AVE Science & Technology Co

AVE Science & Technology Co Equity Ratio

The Equity Ratio of AVE Science & Technology Co (688067.SS) as of Nov 16, 2026 is 88.66 %. In the previous year, Equity Ratio was 88.39 % — a change of 0.31% (higher).

Equity Ratio

88.66 %

YoY

0.31%

Last updated:

Equity Ratio of AVE Science & Technology Co is 2025 88.66 % . Equity Ratio of AVE Science & Technology Co was 2024 88.39 % . It decreases by 0.31% higher compared to the previous year.

The AVE Science & Technology Co Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
84.32 CNY
Jan 1, 2019
84.89 CNY
Jan 1, 2020
79.82 CNY
Jan 1, 2021
87.21 CNY
Jan 1, 2022
86.44 CNY
Jan 1, 2023
87.99 CNY
Jan 1, 2024
88.39 CNY
Jan 1, 2025
88.66 CNY
The AVE Science & Technology Co Equity Ratio history
YEAREquity RatioYoY
88.66 %+0.31%
88.39 %+0.45%
87.99 %+1.80%
86.44 %-0.89%
87.21 %+9.26%
79.82 %-5.98%
84.89 %+0.68%
84.32 %-0.53%
84.77 %+0.75%
84.13 %-5.04%
88.60 %+3.10%
85.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AVE Science & Technology Co Stock analysis

What does AVE Science & Technology Co do? AVE Science & Technology Co., Ltd. generates revenue through the research, development, production, sale, and service of clinical testing and analysis instruments. Its main products include urine formed component analyzer, urine dry chemistry analyzer, urine full item automatic analyzer, automatic stool analyzer, automatic body fluid analyzer, reproductive tract secretion analyzer, and special supporting in vitro diagnostic reagents and medical consumables. These products are primarily sold to inspection departments within medical and health institutions in both domestic and overseas markets. The company serves healthcare facilities that require diagnostic equipment for laboratory testing and patient care. The firm's product portfolio targets healthcare institutions seeking advanced diagnostic tools for efficient clinical analysis. By focusing on specialized instruments like urine and stool analyzers, AVE Science & Technology addresses specific needs in medical testing departments. The company's domestic and international distribution channels ensure broad market access for its diagnostic solutions. AVE Science & Technology's revenue streams are derived from the sale of its comprehensive range of clinical testing instruments and related consumables. The company's domestic market presence and overseas sales contribute to its overall business performance. Its products support routine diagnostic procedures across various healthcare settings, driving consistent demand for its equipment and reagents. AVE Science & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVE Science & Technology Co stock

Equity Ratio of AVE Science & Technology Co is 88.66 % in 2025.

Equity Ratio of AVE Science & Technology Co changed from 88.39 % to 88.66 %, representing a 0.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio AVE Science & Technology Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's AVE Science & Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — AVE Science & Technology Co

All Key Metrics — AVE Science & Technology Co